 Ipsen SA OTC: IPSEY has entered into a long-term strategic partnership to develop, manufacture, and commercialize and Genfit SAs NASDAQ: GNFT elafibranor for Primary Biliary Cholangitis PBC. Under the agreement, Ipsen will pay Genfit up to 480 million, including an upfront cash payment of 120 million and milestone payments up to 360 million, plus tiered double-digit royalties of up to 20. 